Curis, Inc. (@CurisInc) header
Curis, Inc. (@CurisInc) profile picture

NASDAQ: CRIS

Lexington, MA
Joined May 2016
Photo by Curis, Inc. (@CurisInc)Photo by Curis, Inc. (@CurisInc)Photo by Curis, Inc. (@CurisInc)Photo by Curis, Inc. (@CurisInc)Photo by Curis, Inc. (@CurisInc)Photo by Curis, Inc. (@CurisInc)Photo by Curis, Inc. (@CurisInc)Photo by Curis, Inc. (@CurisInc)Photo by Curis, Inc. (@CurisInc)Photo by Curis, Inc. (@CurisInc)
Findings suggest that CA-4948, a novel oral inhibitor of IRAK4 and FLT3, is a promising treatment for heavily pretreated #AML and high-risk #myelodysplasticsyndrome patients: ow.ly/xOSv50JpXtV #ASCO22 #HemOnc #MDS
2
5